So, I'm heavily invested in NYR, have been for many years, but I still think this has a long way to fall.
- The company has been close to a decade in preclinical and are yet to show any expertise in running clinical trials. - Their previous (lead) drug, treating high cholesterol failed due to toxic side effects - Still haven't secured patent IP protection for their asset - NYR has a long track record of missed and slipped timelines - NOX owns a large chunk of NYR, and NOX will start offloading at any positive price movements. This is a massive anchor around NYR neck. - They don't seem to have a plan B if the current TBI drug fails in Phase 1 (as 90%+ of drugs do). - The much-hoped for Walter Reed funding will be non-existent under a Trump presidency.
NYR Price at posting:
9.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)